These cytokines, especially IL-17A, are considered to play a critical role in the pathogenesis of psoriasis, and anti-IL-17A antibody including secukinumab and ixekizumab, anti-IL-17A/IL-17F antibody bimekizumab, and anti-IL-17RA antibody brodalumab which blocks the signaling of IL-17A, IL-17A/F, IL-17F, IL-17C, and IL-17E, show high clinical efficacy in psoriasis (61–64). This evidence concerns the gene IL17RA and psoriasis.